KINETA INC(NASDAQ:KA) stock News

KA Latest News, Press Relases and Analysis

All

Press Releases

a year ago - By: Kineta, Inc.

Kineta Announces Completion of Enrollment in the Monotherapy Arm of the VISTA-101 Phase 1 Clinical Study in Advanced Solid Tumors

a year ago - By: Kineta, Inc.

Kineta Announces KVA12123 Abstract Accepted for Poster Presentation at Society for Immunotherapy of Cancer (SITC) 2024

a year ago - By: Kineta, Inc.

Kineta Announces the Extension of the TuHURA Biosciences Exclusivity and Right of First Offer Agreement for KVA12123, Kineta’s VISTA blocking antibody Currently in Phase 1

a year ago - By: Kineta, Inc.

Kineta, Inc Transitioning from Nasdaq to OTC Markets

a year ago - By: Kintara Therapeutics - Mentions: KTRA

TuHURA Biosciences and Kintara Therapeutics Announce Kineta Inc. Reopens Enrollment for VISTA-101 Clinical Trial Evaluating KVA12123 in Patients with Advanced Solid Tumor Cancer

a year ago - By: InvestorPlace

KA Stock Earnings: Kineta Misses EPS for Q1 2024

2 years ago - By: InvestorPlace

KA Stock Earnings: Kineta Beats EPS for Q4 2023

a year ago - By: Kineta, Inc.

Kineta Reopens Enrollment for the VISTA-101 Clinical Trial Evaluating KVA12123 in Patients with Advanced Solid Tumor Cancer

a year ago - By: InvestorPlace - Mentions: IVP SHPW MORF ZAPP ...

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday

a year ago - By: Kineta, Inc.

Kineta Announces Exclusivity and Right of First Offer Agreement for its VISTA blocking antibody with TuHURA Biosciences

a year ago - By: Kintara Therapeutics - Mentions: KTRA

TuHURA Biosciences Enters into Exclusivity and Right of First Offer Agreement for Kineta, Inc.'s KVA12123 Novel anti-VISTA Checkpoint Inhibitor

a year ago - By: Benzinga - Mentions: PBM TLPH TRVN HSDT ...

12 Health Care Stocks Moving In Thursday's After-Market Session

a year ago - By: InvestorPlace - Mentions: NLSP ASNS MLGO SILK ...

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday

a year ago - By: Benzinga - Mentions: FLFV TRNR EVO LRHC ...

Why Nurix Therapeutics Shares Are Trading Higher By Around 12%; Here Are 20 Stocks Moving Premarket

a year ago - By: InvestorPlace - Mentions: SCNI SHMD NDRA MAXN ...

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday

a year ago - By: InvestorPlace - Mentions: RSLS BNZI SCPX SYTA ...

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday

a year ago - By: BusinessInsider

KA Stock Earnings: Kineta Misses EPS for Q1 2024

a year ago - By: Kineta, Inc.

Kineta Reports First Quarter 2024 Financial Results and Provides Update on its Ongoing Phase 1/2 VISTA-101 Clinical Trial and Corporate Activities

2 years ago - By: Kineta, Inc.

Kineta Reports Initial Clinical Response Data at AACR 2024 of its Ongoing Phase 1/2 VISTA-101 Clinical Trial

2 years ago - By: BusinessInsider

KA Stock Earnings: Kineta Beats EPS for Q4 2023

2 years ago - By: Kineta, Inc.

KINETA INC (KA) Stock News

KA Latest News, Press Relases and Analysis

Kineta Announces Completion of Enrollment in the Monotherapy Arm of the VISTA-101 Phase 1 Clinical Study in Advanced Solid Tumors

Kineta Announces KVA12123 Abstract Accepted for Poster Presentation at Society for Immunotherapy of Cancer (SITC) 2024

Kineta Announces the Extension of the TuHURA Biosciences Exclusivity and Right of First Offer Agreement for KVA12123, Kineta’s VISTA blocking antibody Currently in Phase 1

Kineta, Inc Transitioning from Nasdaq to OTC Markets

TuHURA Biosciences and Kintara Therapeutics Announce Kineta Inc. Reopens Enrollment for VISTA-101 Clinical Trial Evaluating KVA12123 in Patients with Advanced Solid Tumor Cancer

KA Stock Earnings: Kineta Misses EPS for Q1 2024

KA Stock Earnings: Kineta Beats EPS for Q4 2023

Kineta Reopens Enrollment for the VISTA-101 Clinical Trial Evaluating KVA12123 in Patients with Advanced Solid Tumor Cancer

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday

Kineta Announces Exclusivity and Right of First Offer Agreement for its VISTA blocking antibody with TuHURA Biosciences

TuHURA Biosciences Enters into Exclusivity and Right of First Offer Agreement for Kineta, Inc.'s KVA12123 Novel anti-VISTA Checkpoint Inhibitor

12 Health Care Stocks Moving In Thursday's After-Market Session

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday

Why Nurix Therapeutics Shares Are Trading Higher By Around 12%; Here Are 20 Stocks Moving Premarket

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday

KA Stock Earnings: Kineta Misses EPS for Q1 2024

Kineta Reports First Quarter 2024 Financial Results and Provides Update on its Ongoing Phase 1/2 VISTA-101 Clinical Trial and Corporate Activities

Kineta Reports Initial Clinical Response Data at AACR 2024 of its Ongoing Phase 1/2 VISTA-101 Clinical Trial

KA Stock Earnings: Kineta Beats EPS for Q4 2023

Kineta Reports Full Year 2023 Financial Results and Provides Corporate Update